SCHEMBL30309985

SCHEMBL30309985

Cn1cc(C(=O)NCc2ccc(F)c(F)c2)cn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.74
LMNA P02545 1/20 0.64
HPGD P15428 1/20 0.64
MET P08581 1/20 0.62
KLKB1 P03952 1/20 0.53
CACNA1G O43497 1/20 0.49
CACNA1H O95180 1/20 0.49
CACNA1I Q9P0X4 1/20 0.49
MAPK8 P45983 2/20 0.48
ROCK2 O75116 1/20 0.48
ROCK1 Q13464 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPK1 P28482 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
EPHX2 P34913 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
MMP13 P45452 2/20 0.45
PDGFRA P16234 1/20 0.45
PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13211939 0.80 SMN1; SMN2 (0.76) SMN1; SMN2LMNAHPGDKLKB1EPHX2
SCHEMBL359196 0.80 SMN1; SMN2 (0.63) SMN1; SMN2LMNAHPGDKLKB1MAPK8
SCHEMBL12804153 0.78 SMN1; SMN2 (0.57) SMN1; SMN2LMNAHPGDMETKLKB1
SCHEMBL5079750 0.77 CXCR4 (0.58) SMN1; SMN2HPGDMETROCK2ROCK1
SCHEMBL10224605 0.77 SMN1; SMN2 (0.59) SMN1; SMN2LMNAHPGDKLKB1MAPK8
SCHEMBL12804241 0.76 ALDH1A1 (0.61) SMN1; SMN2LMNAHPGDKLKB1NPC1
SCHEMBL1568038 0.75 L3MBTL1 (0.70) ROCK2ROCK1L3MBTL1MAPK1EPHX2
SCHEMBL28813692 0.75 SMN1; SMN2 (0.67) SMN1; SMN2LMNAHPGDKLKB1MMP13
SCHEMBL17546564 0.75 SMN1; SMN2 (0.67) SMN1; SMN2LMNAHPGDKLKB1CLK1
SCHEMBL3459872 0.75 ERCC1 (0.65) NPC1RAB9AEPHX2NR1H4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294524-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-09-05 US disclosed
EP-3466929-B1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS MILLENNIUM PHARM INC (US) 2023-09-06 EP disclosed
US-20230113598-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS BIOGEN IDEC MA INC. 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294524-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 SMN1; SMN2 3723/4885LMNA 3553/4885HPGD 616/4885
US-20230113598-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 SMN1; SMN2 3723/4885LMNA 3553/4885HPGD 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.